In the wake of deep R&D cuts, Bayer flags safety concerns for a top PhIII drug
Less than a week after Bayer announced plans to carve down its internal R&D group, laying off 900 R&D staffers, the German company has tipped …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
